Canaccord Genuity Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH)

Canaccord Genuity analyst Caitlin Cronin reiterated a Hold rating on Zimmer Biomet Holdings today and set a price target of $83.00.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Enovis, and Smith & Nephew Snats. According to TipRanks, Cronin has an average return of 8.5% and a 46.61% success rate on recommended stocks.

In addition to Canaccord Genuity, Zimmer Biomet Holdings also received a Hold from Citi’s Joanne Wuensch in a report issued today. However, on the same day, Barclays maintained a Sell rating on Zimmer Biomet Holdings (NYSE: ZBH).

Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 billion and a net profit of $139.5 million. In comparison, last year the company earned a revenue of $2.02 billion and had a net profit of $239.5 million

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year. Last month, Lori Winkler, the SVP and CHRO of ZBH sold 2,650.00 shares for a total of $250,849.00.